FUNDAMENTALS · Fundamentals · TW Consumer Defensive

Dr. Wu Skincare (6523) Fundamentals 2026 — P/E 14.5x, Revenue Analysis | SniperIQ

Dr. Wu Skincare (6523) is a TW-listed Consumer Defensive company in Household & Personal Products with a market capitalization of NT$4.1B, trading at NT$90.10 on the TWO. This SniperIQ fundamentals page covers Dr. Wu Skincare's valuation (P/E 14.5x, P/B 3.0x), profitability (net margin 25.5%), revenue (NT

.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT$4.1B
P/E (TTM)14.5x
Net Margin25.5%
Revenue (FY25)NT
.2B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Dr. Wu Skincare's market cap?

Dr. Wu Skincare (6523) has a market capitalization of approximately NT$4.1B, trading at NT$90.10 on the TWO. Market cap moves with the live share price.

What is Dr. Wu Skincare's P/E ratio?

Dr. Wu Skincare's trailing twelve-month P/E ratio is 14.5x, with a price-to-book (P/B) of 3.0x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.

How profitable is Dr. Wu Skincare?

Dr. Wu Skincare runs a net profit margin of 25.5%, a gross margin of 67.4%, and an operating margin of 31.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Dr. Wu Skincare generate?

Dr. Wu Skincare reported revenue of NT

.2B for fiscal year 2025, with net income of NT
50M and earnings per share (EPS) of 7.78. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Dr. Wu Skincare pay a dividend?

Dr. Wu Skincare offers a trailing dividend yield of about 11.1%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.

Is Dr. Wu Skincare financially healthy?

Dr. Wu Skincare carries a debt-to-equity ratio of 0.03x and a current ratio of 4.47x, with a market beta of -0.06. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Dr. Wu Skincare a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dr. Wu Skincare (6523) the key facts are: market cap NT$4.1B, P/E 14.5x, revenue NT

.2B, 52-week range 89-131. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.

Track Dr. Wu Skincare's full fundamentals live

Get Dr. Wu Skincare's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.